WO2014165713A3 - Traitement des affections inflammatoires par modulation de l'activité hyaluronane et hyaluronidase - Google Patents

Traitement des affections inflammatoires par modulation de l'activité hyaluronane et hyaluronidase Download PDF

Info

Publication number
WO2014165713A3
WO2014165713A3 PCT/US2014/032893 US2014032893W WO2014165713A3 WO 2014165713 A3 WO2014165713 A3 WO 2014165713A3 US 2014032893 W US2014032893 W US 2014032893W WO 2014165713 A3 WO2014165713 A3 WO 2014165713A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronan
inflammatory conditions
modulation
treatment
hyaluronidase activity
Prior art date
Application number
PCT/US2014/032893
Other languages
English (en)
Other versions
WO2014165713A2 (fr
Inventor
George Liu
Pierre Kyme
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Priority to EP14780170.8A priority Critical patent/EP2981283A4/fr
Priority to US14/782,269 priority patent/US9763969B2/en
Priority to CA2907586A priority patent/CA2907586A1/fr
Priority to CN201480020033.0A priority patent/CN105120889B/zh
Priority to KR1020157027060A priority patent/KR20150138219A/ko
Publication of WO2014165713A2 publication Critical patent/WO2014165713A2/fr
Publication of WO2014165713A3 publication Critical patent/WO2014165713A3/fr
Priority to US15/684,208 priority patent/US20170348338A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)

Abstract

Cette invention concerne des compositions, des méthodes et des kits s'y rapportant pour traiter diverses affections inflammatoires et infections. Les compositions thérapeutiques comprennent certaines hyaluronidases capables de générer des disaccharides d'hyaluronane quand elles sont combinées à l'hyaluronane, et/ou les disaccharides d'hyaluronane eux-mêmes, et/ou des inhibiteurs d'hyaluronidase inflammatoires. L'utilisation desdits inhibiteurs d'hyaluronidase pour traiter certaines infections chez un individu est en outre décrite.
PCT/US2014/032893 2013-04-03 2014-04-03 Traitement des affections inflammatoires par modulation de l'activité hyaluronane et hyaluronidase WO2014165713A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP14780170.8A EP2981283A4 (fr) 2013-04-03 2014-04-03 Traitement des affections inflammatoires par modulation de l'activité hyaluronane et hyaluronidase
US14/782,269 US9763969B2 (en) 2013-04-03 2014-04-03 Treatment of inflammatory conditions with hyaluronan disaccharide
CA2907586A CA2907586A1 (fr) 2013-04-03 2014-04-03 Traitement des affections inflammatoires par modulation de l'activite hyaluronane et hyaluronidase
CN201480020033.0A CN105120889B (zh) 2013-04-03 2014-04-03 通过调节乙酰透明质酸和透明质酸酶活性而治疗炎性病状
KR1020157027060A KR20150138219A (ko) 2013-04-03 2014-04-03 히알루로난 및 히알루로니다제 활성의 조절에 의한 염증성 병태의 치료
US15/684,208 US20170348338A1 (en) 2013-04-03 2017-08-23 Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808063P 2013-04-03 2013-04-03
US61/808,063 2013-04-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/782,269 A-371-Of-International US9763969B2 (en) 2013-04-03 2014-04-03 Treatment of inflammatory conditions with hyaluronan disaccharide
US15/684,208 Division US20170348338A1 (en) 2013-04-03 2017-08-23 Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity

Publications (2)

Publication Number Publication Date
WO2014165713A2 WO2014165713A2 (fr) 2014-10-09
WO2014165713A3 true WO2014165713A3 (fr) 2015-06-18

Family

ID=51659352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/032893 WO2014165713A2 (fr) 2013-04-03 2014-04-03 Traitement des affections inflammatoires par modulation de l'activité hyaluronane et hyaluronidase

Country Status (6)

Country Link
US (2) US9763969B2 (fr)
EP (1) EP2981283A4 (fr)
KR (1) KR20150138219A (fr)
CN (1) CN105120889B (fr)
CA (1) CA2907586A1 (fr)
WO (1) WO2014165713A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9763969B2 (en) 2013-04-03 2017-09-19 Cedars-Sinai Medical Center Treatment of inflammatory conditions with hyaluronan disaccharide
US20190022207A1 (en) * 2015-07-30 2019-01-24 Cedars-Sinai Medical Center Compositions and Methods for Treating Acne
AU2017255833B2 (en) 2016-04-25 2022-09-01 Mizhou Hui Application of small-molecule hyaluronic acid fragment
US11306157B2 (en) 2018-12-21 2022-04-19 California Institute Of Technology Expedient synthesis of core disaccharide building blocks from natural polysaccharides for heparan sulfate oligosaccharide assembly
WO2021213623A1 (fr) * 2020-04-20 2021-10-28 Pharmact Holding Ag Polypeptide hyaluronidase bactérien modifié, procédé de production, compositions pharmaceutiques et leurs utilisations
WO2023067008A1 (fr) * 2021-10-19 2023-04-27 Pharmact Holding Ag Production d'un polypeptide hyaluronidase bactérien modifié purifié, compositions pharmaceutiques et leurs utilisations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086852A1 (en) * 1998-05-14 2002-07-04 Cantor Jerome O. Method for treating respiratory disorders associated with pulmonary elastic fiber injury
US20070099867A1 (en) * 2005-05-24 2007-05-03 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
WO2011156445A1 (fr) * 2010-06-08 2011-12-15 University Of Utah Research Foundation Applications de hyaluronane partiellement ou entièrement sulfaté
US20130059769A1 (en) * 2010-05-10 2013-03-07 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
US20130072452A1 (en) * 2011-09-16 2013-03-21 China Medical University Pharmaceutical composition and method for inhibiting inflammation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (fr) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
US20030162760A1 (en) 1999-01-26 2003-08-28 Eiko Masatsuji Dermal agent
ITMI20021866A1 (it) 2002-08-30 2004-02-29 Luigi Allegra Preparazione farmaceutica in forma colloidale utile nella cura delle affezioni cutanee.
EP2330213A1 (fr) 2003-03-05 2011-06-08 Halozyme, Inc. Glycoprotéine d'hyaluronidase soluble (sHASEGP), son procédé de préparation, utilisations et compositions pharmaceutiques le comportant
JP2007084509A (ja) * 2005-09-26 2007-04-05 Toshitsu Kagaku Kenkyusho:Kk 細胞賦活剤
JP5457675B2 (ja) * 2006-10-17 2014-04-02 株式会社ヒアルロン酸研究所 アトピー性皮膚炎の治療薬又は予防薬
CA2686931A1 (fr) * 2007-05-11 2008-11-20 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
US20100323983A1 (en) * 2007-05-11 2010-12-23 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof, and uses thereof
US8288142B2 (en) 2007-06-19 2012-10-16 Uvarkina Tamara P Hyaluronidase and method of use thereof
JP4754532B2 (ja) * 2007-07-09 2011-08-24 生化学工業株式会社 ヒアルロン酸オリゴ糖を有効成分とする治療剤
US9763969B2 (en) 2013-04-03 2017-09-19 Cedars-Sinai Medical Center Treatment of inflammatory conditions with hyaluronan disaccharide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086852A1 (en) * 1998-05-14 2002-07-04 Cantor Jerome O. Method for treating respiratory disorders associated with pulmonary elastic fiber injury
US20070099867A1 (en) * 2005-05-24 2007-05-03 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
US20130059769A1 (en) * 2010-05-10 2013-03-07 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
WO2011156445A1 (fr) * 2010-06-08 2011-12-15 University Of Utah Research Foundation Applications de hyaluronane partiellement ou entièrement sulfaté
US20130072452A1 (en) * 2011-09-16 2013-03-21 China Medical University Pharmaceutical composition and method for inhibiting inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2981283A4 *

Also Published As

Publication number Publication date
WO2014165713A2 (fr) 2014-10-09
US9763969B2 (en) 2017-09-19
US20170348338A1 (en) 2017-12-07
EP2981283A2 (fr) 2016-02-10
CA2907586A1 (fr) 2014-10-09
EP2981283A4 (fr) 2017-07-05
CN105120889B (zh) 2018-04-13
KR20150138219A (ko) 2015-12-09
US20160022715A1 (en) 2016-01-28
CN105120889A (zh) 2015-12-02

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
WO2015073587A3 (fr) Complexes membrane synthétique- récepteur
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
CA2900779C (fr) Compositions et methodes de traitement des affections des maladies neurodegeneratives et de myocardiopathies
EA201591743A1 (ru) СТИМУЛЯТОРЫ sGC
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
WO2014165713A3 (fr) Traitement des affections inflammatoires par modulation de l'activité hyaluronane et hyaluronidase
WO2014035140A3 (fr) Composés et compositions pour la modulation de l'activité histone méthyltransférase
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
WO2019040106A3 (fr) Composés, sels associés et méthodes pour le traitement de maladies
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
PH12016501349A1 (en) Hydroxy formamide derivatives and their use
MY178390A (en) Inhibitors of iap
SG10201804952QA (en) Glucosylceramide synthase inhibitors
TN2015000427A1 (en) Salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2016016407A (es) Composiciones biofotonicas termoestables y usos de las mismas.
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
WO2019040105A3 (fr) Composés, sels de ces composés et procédés pour le traitement de maladies
MX366805B (es) Uso de sulfato de zinc coceth como un agente antibacteriano en contra de propionibacterium acnes.
MX2017000184A (es) Agentes de interaccion enzimatica.
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
EA201501176A1 (ru) Замещенные бензоксазолы

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14780170

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2014780170

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2907586

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20157027060

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14782269

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14780170

Country of ref document: EP

Kind code of ref document: A2